BIP Wealth LLC Boosts Amgen Stake by Over 800%

Institutional investor significantly increases position in biotech giant during Q4 2025

Apr. 8, 2026 at 8:36am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, intricate metal machinery and gears in shades of steel gray, bronze, and black, conceptually representing the complex financial infrastructure and institutional power of the biotech industry.Institutional investor activity in Amgen shares reflects broader confidence in the biotech company's future growth potential.Thousand Oaks Today

BIP Wealth LLC, an investment management firm, significantly increased its holdings in Amgen Inc. (NASDAQ: AMGN) during the fourth quarter of 2025, boosting its stake by over 800% to 9,872 shares worth $3.23 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a focus on developing innovative human therapeutics to treat serious illnesses. Institutional investor activity in Amgen shares can provide insights into market sentiment and future growth prospects for the company.

The details

According to a recent SEC filing, BIP Wealth LLC raised its holdings in Amgen by 808.2% during the fourth quarter, adding 8,785 shares to its position. The firm now owns a total of 9,872 shares of the medical research company's stock, valued at $3.23 million at the end of the quarter.

  • BIP Wealth LLC increased its Amgen stake during the fourth quarter of 2025.

The players

BIP Wealth LLC

An investment management firm that significantly increased its stake in Amgen during the fourth quarter of 2025.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The substantial increase in BIP Wealth LLC's Amgen position suggests the investment firm sees strong growth potential in the biotech company's pipeline and future prospects. This institutional investor activity could signal broader market confidence in Amgen's ability to continue delivering value for shareholders.